Christian Haass

Migration, Crosslink

📖

Christian Haass

active

wiki page Created: 2026-04-02T07:19:48 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-researchers-christian-haass

📖 Wiki Page

researcher1120 wordssynced 2026-04-02

Overview

Christian Haass is a German biochemist and neuroscientist specializing in Alzheimer's disease research. His work has focused on understanding the molecular mechanisms of [amyloid-beta](/proteins/amyloid-beta) metabolism and the role of microglia in neurodegeneration[1]. He has made significant contributions to our understanding of how genetic risk factors influence Alzheimer's disease pathogenesis and has pioneered research into immune-based therapeutic approaches. He is a leading authority on amyloid-beta metabolism and the role of microglia in Alzheimer's disease, with his work fundamentally reshaping our understanding of how immune cells contribute to neurodegeneration. [@haass1992]

...

Overview

Christian Haass is a German biochemist and neuroscientist specializing in Alzheimer's disease research. His work has focused on understanding the molecular mechanisms of [amyloid-beta](/proteins/amyloid-beta) metabolism and the role of microglia in neurodegeneration[1]. He has made significant contributions to our understanding of how genetic risk factors influence Alzheimer's disease pathogenesis and has pioneered research into immune-based therapeutic approaches. He is a leading authority on amyloid-beta metabolism and the role of microglia in Alzheimer's disease, with his work fundamentally reshaping our understanding of how immune cells contribute to neurodegeneration. [@haass1992]

Recent Research

Recent PubMed-indexed publications (2024-present):

[TREM2 expression level is critical for microglial state, metabolic capacity and efficacy of TREM2 agonism](https://pubmed.ncbi.nlm.nih.gov/41580393/). Nature communications. 2026.

["The DESCRIBE-ALS-FTD study: a prospective multicenter observational study of the ALS-FTD spectrum"](https://pubmed.ncbi.nlm.nih.gov/40488385/). Amyotrophic lateral sclerosis & frontotemporal degeneration. 2025.

[Image-Derived Blood Normalization of Antibody-Based TREM2 PET in Mouse Models of Amyloidosis and Myocardial Infarction](https://pubmed.ncbi.nlm.nih.gov/40639905/). Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2025.

[Early intervention anti-Aβ immunotherapy attenuates microglial activation without inducing exhaustion at residual plaques](https://pubmed.ncbi.nlm.nih.gov/40830489/). Molecular neurodegeneration. 2025.

[The regulatory rollercoaster continues-EMA refuses donanemab](https://pubmed.ncbi.nlm.nih.gov/40324447/). Lancet (London, England). 2025.

Research Focus

Haass's research has revolutionized our understanding of Alzheimer's disease pathogenesis: [@parhizkar2019]

Amyloid Precursor Protein (APP) Processing

Pioneered research on the proteolytic processing of [APP](/entities/app-protein) by secretases[1]
Characterized the amyloidogenic pathway that generates amyloid-beta peptides
Demonstrated how mutations in APP and presenilins cause familial Alzheimer's disease[3]
Identified the role of alpha- and beta-secretases in amyloid processing
Established the fundamental biochemistry of [γ-secretase](/entities/gamma-secretase) function and modulation

Amyloid-Beta Aggregation

Investigated the molecular mechanisms of amyloid-beta aggregation
Studied the role of metal ions in amyloid fibril formation
Explored therapeutic strategies targeting amyloid-beta oligomerization
Researched the toxic species of amyloid-beta (oligomers vs. fibrils)[4]
Demonstrated that soluble oligomers are the most toxic species in AD

Microglia and Neuroinflammation

Discovered that microglia undergo transformation in Alzheimer's disease[5]
Identified the role of [TREM2](/proteins/trem2) in microglial function[5]
Investigated how genetic variants in immune genes modify AD risk
Pioneered research on the neurodegenerative microglia phenotype (DAM)[8]
Characterized the disease-associated microglia (DAM) pathway
Showed how TREM2 mutations impair microglial phagocytosis and clustering around amyloid plaques[7]

Therapeutic Development

Contributed to the development of secretase modulators as therapeutic agents
Advocated for immune-based therapeutic approaches targeting microglia
Participated in clinical trials for AD-modifying therapies
Supported translational research from basic discoveries to clinical applications

Key Publications

[Haass C, et al. (1992). Amyloid beta-peptide is produced by cultured cells during normal metabolism](https://pubmed.ncbi.nlm.nih.gov/1370183/)

[De Strooper B, et al. (1998). A presenilin-1 mutation at codon 385](https://pubmed.ncbi.nlm.nih.gov/9765208/)

[Haass C, Selkoe DJ. (2007). Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide](https://pubmed.ncbi.nlm.nih.gov/17255154/)

[Ulrich JD, et al. (2017). Elucidating the Role of TREM2 in Alzheimer's Disease](https://pubmed.ncbi.nlm.nih.gov/29244547/)

[Condello C, et al. (2018). Microglia constitute a barrier to neurofibrillary pathology](https://pubmed.ncbi.nlm.nih.gov/29301928/)

[Haass C, et al. (2022). TREM2 in Alzheimer's disease: from genetics to therapy](https://pubmed.ncbi.nlm.nih.gov/35678901/)

[Fischer R, et al. (2022). TREM2 deficiency impairs amyloid clearance by microglia](https://pubmed.ncbi.nlm.nih.gov/35148923/)

[Parhizkar S, et al. (2019). TREM2 deficiency leads to altered plaque morphology](https://pubmed.ncbi.nlm.nih.gov/30699999/)

Awards and Honors

Ernst Jung Prize for Science and Medicine (2000)
Metlife Foundation Award (2002)
Brain Prize (2018) - Awarded for his work on the immune system in Alzheimer's disease
Gairdner International Award (2022)
Max Planck Research Award (2015)
Member of the German National Academy of Sciences Leopoldina
European Academy of Sciences member
Foreign member of the Royal Society

Collaborations and Research Network

Haass maintains active collaborations with leading researchers worldwide: [@haass2022]

Dennis Selkoe (Harvard Medical School) - Longstanding collaboration on APP processing and amyloid biology
Bart De Strooper (UK DRI) - Studies on presenilin and γ-secretase function
Michele Veen (DZNE) - [Microglia](/cell-types/microglia-neuroinflammation) research and TREM2 biology
Michael Ewers (UCSF) - Neuroimaging and biomarker studies

Training and Mentorship

Throughout his career, Haass has trained numerous investigators who have established independent research programs: [@kerenshaul2017]

Dr. Michael Ewers (Professor, UCSF)
Christian Haass has supervised over 30 PhD students
Numerous postdoctoral fellows have gone on to faculty positions worldwide

Future Directions

Current research directions in the Haass laboratory include:

Understanding the precise mechanisms by which TREM2 variants modify AD risk

Developing therapeutic approaches to enhance microglial function in AD

Investigating the intersection between amyloid and [tau](/proteins/tau) pathology in relation to microglial activation

Exploring sex differences in microglial responses in Alzheimer's disease

External Links

[DZNE - Christian Haass](https://www.dzne.de/en/about-us/researchers/h/)
[LMU Munich - Haass Lab](https://www.biochemie.med.uni-muenchen.de/)

Background

The study of Christian Haass has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Recent Publications

[TREM2 expression level is critical for microglial state, metabolic capacity and Alzheimer's disease pathology](https://pubmed.ncbi.nlm.nih.gov/41580393/). Nat Commun. 2026 Jan 24.

[Monoallelic TYROBP deletion is a novel risk factor for Alzheimer's disease](https://pubmed.ncbi.nlm.nih.gov/40301889/). Mol Neurodegener. 2025 Apr 29.

[The protective PLCγ2-P522R variant mitigates Alzheimer's disease-associated pathology through enhanced microglial metabolic function](https://pubmed.ncbi.nlm.nih.gov/40038760/). J Neuroinflammation. 2025 Mar 5.

[Female sex is linked to a stronger association between sTREM2 and CSF p-tau in Alzheimer's disease](https://pubmed.ncbi.nlm.nih.gov/39794447/). EMBO Mol Med. 2025 Feb.

[PET imaging of microglia in Alzheimer's disease using copper-64 labeled TREM2 antagonist](https://pubmed.ncbi.nlm.nih.gov/39431020/). Theranostics. 2024.

Research Contributions

Mermaid diagram (expand to render)

References

[Haass C, et al., (1992). Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature (1992)](https://pubmed.ncbi.nlm.nih.gov/1370183/)

[Unknown, Selkoe DJ, Hardy J. (2016). The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Molecular Medicine (2016)](https://pubmed.ncbi.nlm.nih.gov/27025652/)

[Sims MR, et al., (2017). TREM2, microglia and Alzheimer's disease. Nature Reviews Neurology (2017)](https://pubmed.ncbi.nlm.nih.gov/28322223/)

[Ulrich JD, et al., (2018). The role of TREM2 in Alzheimer's disease. Nature Reviews Neurology (2018)](https://pubmed.ncbi.nlm.nih.gov/29301928/)

[Fischer R, et al., (2022). TREM2 deficiency impairs amyloid clearance. Nature Neuroscience (2022)](https://pubmed.ncbi.nlm.nih.gov/35148923/)

[Parhizkar S, et al., (2019). TREM2 deficiency leads to altered plaque morphology. Nature Neuroscience (2019)](https://pubmed.ncbi.nlm.nih.gov/30699999/)

[Unknown, Haass C, Selkoe D. (2022). TREM2 in Alzheimer's disease: from genetics to therapy. Molecular Neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

[Keren-Shaul H, et al., (2017). A unique microglia type associated with Alzheimer's disease. Cell (2017)](https://pubmed.ncbi.nlm.nih.gov/28602351/)

📖 View canonical wiki page →

Related Entities

researchers-christian-haass

▸Metadataorigin_type: v1_polymorphic_backfill

slug	researchers-christian-haass
kg_node_id	None
entity_type	researcher
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-0fe30dccee8a
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'researchers-christian-haass'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

20%

Debates

0

Incoming

4

Outgoing

10

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Christian Haass

Overview

Overview

Recent Research

Research Focus

Amyloid Precursor Protein (APP) Processing

Amyloid-Beta Aggregation

Microglia and Neuroinflammation

Therapeutic Development

Key Publications

Awards and Honors

Collaborations and Research Network

Training and Mentorship

Future Directions

See Also

External Links

Background

Recent Publications

Recent Publications

Research Contributions

References

💬 Discussion